CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.309
-0.011 (-3.44%)
Apr 28, 2026, 3:58 PM EST
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
419.67M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Silence Therapeutics | 559.00K |
| Northwest Biotherapeutics | 1.38M |
| Vaxart | 237.26M |
| BioStem Technologies | 47.48M |
| Nuo Therapeutics | 3.31M |
CytoDyn News
- 2 days ago - CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer - GlobeNewsWire
- 6 days ago - CytoDyn to Host Investor Webcast - GlobeNewsWire
- 7 days ago - CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 - GlobeNewsWire
- 7 days ago - CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study - GlobeNewsWire
- 9 days ago - CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 - GlobeNewsWire
- 15 days ago - CytoDyn to Present at the AACR Annual Meeting 2026 - GlobeNewsWire
- 5 weeks ago - CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer - GlobeNewsWire
- 7 weeks ago - CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab - GlobeNewsWire